Literature DB >> 12727937

Clinical review 157: Pathophysiology of Graves' ophthalmopathy: the cycle of disease.

Rebecca S Bahn1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12727937     DOI： 10.1210/jc.2002-030010

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  53 in total

Review 1.  Pharmacological treatments for thyroid eye disease.

Authors:  Sara P Modjtahedi; Bobeck S Modjtahedi; Ahmad M Mansury; Dinesh Selva; Raymond S Douglas; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial.

Authors:  T-C Chang; S-L Liao
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

3.  Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease.

Authors:  B Gopinath; R Musselman; N Beard; S El-Kaissi; J Tani; C-L Adams; J R Wall
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

4.  Thyroid-associated orbitopathy: Current insights into the pathophysiology, immunology and management.

Authors:  Rina Bhatt; Christine C Nelson; Raymond S Douglas
Journal:  Saudi J Ophthalmol       Date:  2010-11-11

5.  Semiautomatic regional segmentation to measure orbital fat volumes in thyroid-associated ophthalmopathy. A validation study.

Authors:  M Comerci; A Elefante; D Strianese; R Senese; P Bonavolontà; B Alfano; B Bonavolontà; A Brunetti
Journal:  Neuroradiol J       Date:  2013-08-27

Review 6.  Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment.

Authors:  James A Garrity; Rebecca S Bahn
Journal:  Am J Ophthalmol       Date:  2006-07       Impact factor: 5.258

7.  [Surgical therapy in Graves' orbitopathy].

Authors:  J Kaminsky; G J Ridder; A Eckstein; M Metzger; F Beisse
Journal:  Ophthalmologe       Date:  2011-05       Impact factor: 1.059

8.  [Clinical and neuroradiological diagnostics in Graves' orbitopathy].

Authors:  F Beisse; C Pieh-Beisse; W A Lagrèze; C Hader
Journal:  Ophthalmologe       Date:  2011-05       Impact factor: 1.059

Review 9.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

10.  Autoantibody against aldehyde dehydrogenase 2 could be a biomarker to monitor progression of Graves' orbitopathy.

Authors:  Kai-Chun Cheng; Yu-Jen Wu; Kai-Hung Cheng; Kai-Yuan Cheng; Kuo-Jen Chen; Wen-Chuan Wu; Po-Yen Lee; Cheng-Hsien Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-03       Impact factor: 3.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.